Company news
Shionogi & Co., Ltd. (TSE:4507) news
Every Shionogi & Co., Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Shionogi Announces U.S. Government Procurement of Fetroja through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
August 31, 2026
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
August 28, 2026
Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)
August 3, 2026
Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS
July 30, 2026
Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*
July 28, 2026
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
July 23, 2026
Kirin Group and Blackmores to Launch New Cognizin® Cognitive Support Supplements in Australia and New Zealand
July 22, 2026
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
July 16, 2026
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
June 24, 2026
Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19
June 19, 2026
Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis
June 18, 2026
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
June 1, 2026
Shionogi : FY2025 Financial Results
May 12, 2026
Shionogi : FY2025 Supplement
May 12, 2026
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
April 8, 2026
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
April 7, 2026
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
April 1, 2026
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109
March 24, 2026
Shionogi & Co., Ltd. - ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan
March 20, 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
March 18, 2026
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
February 25, 2026
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
February 25, 2026
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
February 17, 2026
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
February 10, 2026
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 9, 2026
Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize
January 19, 2026
Shionogi - Announcement of the Conclusion of a Joint Research and Development Agreement and Investment Agreement with Salubritas Therapeutics Aimed at Demonstrating the Improvements of Hearing Function
December 24, 2025
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
December 22, 2025
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
December 11, 2025
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
October 17, 2025
Gareth Morgan Named President of Qpex Biopharma, Inc.
October 15, 2025
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
October 15, 2025
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
October 9, 2025
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
September 19, 2025
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
September 10, 2025
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
September 3, 2025
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
September 2, 2025
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
July 14, 2025
Shionogi Implements Stibo Systems MDM Solution
July 10, 2025
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
July 3, 2025
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 2, 2025
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older
June 30, 2025
Shionogi : FY2024 Supplement
May 12, 2025
Shionogi : FY2024 Financial Results
May 12, 2025
Shionogi : Agreement on the Absorption-Type Split of JT Pharmaceutical Division and Acquisition of Shares of Akros, and Commencement of Tender Offer for TORII
May 7, 2025
Shionogi & Co., Ltd. - Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand
April 3, 2025
Shionogi & Co., Ltd. - Approval for Fetroja in South Korea
February 24, 2025
Shionogi Obtains Domestic Manufacturing and Marketing Approval for the Digital Therapeutic App ENDEAVORRIDE for Pediatric Attention-Deficit, Hyperactivity Disorder
February 19, 2025